贝伐单抗联合托泊替康治疗铂耐药性卵巢癌对血清Smac及SMRP水平的影响

The effect of bevacizumab combined with topotecan on serum Smac and SMRP in platinum resistant ovarian cancer

目的:研究贝伐单抗(BEV)联合托泊替康对铂耐药性卵巢癌患者血清第二线粒体caspase激活蛋白(Smac)及可溶性间皮素相关蛋白(SMRP)的影响。方法:选取2014年10月至2016年10月在四川省巴中市中心医院诊治的84例卵巢癌患者作为研究对象,按随机数字表法分为研究组和对照组,每组42例。对照组患者采用托泊替康治疗,研究组患者采用BEV联合托泊替康进行治疗。比较两组客观有效率(ORR)、中位无进展生存期(PFS)、中位总生存时间(OS)、血清Smac和SMRP水平及不良反应发生率。结果:研究组ORR、PFS及OS均高于对照组(均P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后,两组血清SMRP水平显著降低,Smac水平明显升高,且研究组变化更为显著(均P<0.05)。结论:BEV联合托泊替康治疗铂耐药的卵巢癌患者,疗效较好,可延缓疾病进展,延长生存时间,其作用可能与改善患者血清Smac及SMRP水平有关。

Objective:To study the effect of bevacizumab combined with topotecan on serum second mitochondrical activator of caspase(Smac)and soluble mesothelin related proteins(SMRP)in platinum resistant ovarian cancer patients.Methods:A total of 84 patients with ovarian cancer treated in our hospital from October 2014 to October 2016 were selected and randomly divided into a study group and a control group,with 42 cases in each group.The patients in the control group were treated with topotecan,and patients in the study group were treated with bevacizumab combined with topotecan.The objective effective rate(ORR),median progression-free survival(PFS)time,median total survival time,serum Smac and SMRP levels and the incidence of adverse reactions were compared.Results:The ORR,PFS,and OS in the study group were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The level of SMRP was decreased after treatment whereas the level of Smac was increased in both groups,and the changes were more marked in the study group(P<0.05).Conclusion:Bevacizumab combined with topotecan had better curative effect on platinum resistant ovarian cancer.It could delay the progression of disease and prolong the survival time,which may be related to the improvement of serum Smac and SMRP levels.